Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care
Recruiting now · Not applicable
Conditions studied: Skin Cancer
In brief
Background: Artificial intelligence has in numerous studies shown high accuracy in detecting skin cancer when trained on various databases of dermatoscopic images. However, there are very few prospective studies conducted in real clinical settings directed at patients seeking healthcare for assessment of skin lesions, and nosuch studies at all in primary care, where the majority of patients are managed. Project aim: To study the accuracy, reliability, and clinical utility of an AI-based decision support system (Dermalyser), developed for primary care, in distinguishing skin cancer from benign lesions. Method: Cluster-randomized controlled trial at approx. 30 primary care centers in Sweden, Germany, Scotland, the Netherlands and Australia. At study start, the participating primary care centres in each country are equally randomised to either be enabled to use the Dermalyser (intervention phase) or to assess patients according to the standard clinical procedure (control phase). When half of the intended sample size (i.e. 1500 of 3000 participants) have been included, the primary care centres switch phase from intervention to control, or vice versa. During the intervention phase, the physicians may use (if found indicated) Dermalyser as a part of their clinical evaluation, whereas during the control phase the physicians follow their ordinary diagnostic routine without support from Dermalyser. This will direct the participants to either an intervention or a control cohort. Both groups will be followed for up to 5 years, with regard to the tumour diagnoses, proportions of skin cancer/benign lesions, and morbidity and mortality in skin cancer. Possible between-group differences will be investigated statistically. Potential benefits: If the Dermalyser prooves to be safe and diagnotically reliability, it could enhance the chance of detecting skin cancer in early stage in primary care, and to reduce the proportion of benign skin lesion unnecessarily excised or referred to dermatologist.
Key facts
- Study ID
- NCT06932172
- Run by
- Linkoeping University
- People needed
- 3000
- Starts
- 2025-11-04
- Expected to finish
- 2031-12-31
- Last updated by the study team
- 2026-01-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Patients attending a primary care facility in order to have one or more skin lesions checked for skin cancer, or patients presenting with one or more skin lesions raising suspicion of skin cancer when noticed by the primary care physician.
- Willingness and ability to provide informed consent.
You may not qualify if…
- Individuals with skin type V and VI according to the Fitzpatrick's scale (darker brown or black coloured skin)
Where it is running
- Finspång Primary Healthcare Centre — Finspång, Docent, Sweden (enrolling)
- Valla Primary Healthcare Centre — Linköping, Docent, Sweden (enrolling)
- Kärna Primary Care Centre — Linköping, Docent, Sweden (enrolling)
- Mjölby Primary Care Centre — Mjölby, Docent, Sweden (enrolling)
- Vikbolandet Primary Care Centre — Norrköping, Docent, Sweden (enrolling)
- Åby Primary Healthcare Centre — Norrköping, Docent, Sweden (enrolling)
- Skärvet Primary Healthcare Centre — Vaxjo, Docent, Sweden (enrolling)
- Ekholmen Primary Healthcare Centre — Linköping, Sweden (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.